Billions of dollars have been invested in young artificial intelligence drug discovery companies, while several large firms have begun integrating AI technology across their operations

Overview Debates Related claims Topics Sources

The World Health Organization Regional Office for Africa used artificial intelligence analysis in the Democratic Republic of Congo to reduce situation report generation time from a full working day to one hour.

Response teams in the Democratic Republic of Congo fighting the Bundibugyo strain of Ebola virus used Anthropic's Claude model to evaluate digitized health worker field reports.

The European Academies Science Advisory Council report warned that routine automation by artificial intelligence risks professional deskilling among medical staff during system outages.

Vir Biotechnology utilizes its PRO-XTEN masking technology and proprietary dAIsY AI platform to design dual-masked T-cell engager candidates against solid tumors

Professor Thomas Thesen of Dartmouth University stated that artificial intelligence chatbots create an explainability black-box problem by failing to explain pattern recognition in human-understandable language.

Merck officially opened Advance, a 120,000-square-foot research facility featuring automated robotics and AI, at its West Point, Pennsylvania campus on October 14, 2026.

Isomorphic Labs established partnerships with major pharmaceutical companies while planning to design internal therapeutic drugs using artificial intelligence.

Isomorphic Labs held funding discussions at a valuation of at least $40 billion, five months after raising $2.1 billion led by Thrive Capital.

Moody's warned in August 2026 that banks deploying AI risk systemic dependency on concentrated technology providers, specifically naming OpenAI and Anthropic.

Bank of England Governor Andrew Bailey described frontier AI threat capabilities as the most immediate cyber risk facing global financial systems in an August 31, 2026 letter.

On October 15, 2026, U.K. drugmaker AstraZeneca announced a partnership with artificial intelligence startup Insitro to discover new treatments for cardiometabolic diseases

AstraZeneca agreed to make an upfront payment of $40 million to Insitro for the artificial intelligence drug discovery collaboration announced on October 15, 2026

The research collaboration between AstraZeneca and Insitro, announced on October 15, 2026, targets metabolic dysfunction-associated steatohepatitis, a fatty liver condition, and cardiomyopathies, which are diseases affecting the heart muscle

Swiss pharmaceutical maker Roche agreed earlier in 2026 to build a supercomputer in partnership with technology company Nvidia for artificial intelligence drug discovery

Last month, pharmaceutical company Novo Nordisk partnered with artificial intelligence laboratory Anthropic to utilize the Claude Science platform for drug research

Publicly traded artificial intelligence drug discovery companies have struggled following their initial public offerings amid industry concerns regarding overstated capabilities

Iambic Therapeutics has partnered with drugmakers Takeda Pharmaceutical, AbbVie, Jazz Pharmaceuticals, and Revolution Medicines for its artificial intelligence technology platform

Iambic Therapeutics stated in its initial public offering filing that it uses artificial intelligence across drug research to identify potential medicines, optimize them, and predict clinical trial outcomes

Proscia's software converts physical pathology slides into digital images that can be stored, reviewed, and analyzed using artificial intelligence tools.

Proscia's software platform connects slide scanners, laboratory information systems, image-analysis applications, and artificial intelligence tools into a unified operating layer.